{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_19424", "batch_size": 200, "batch_pos": 150, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb, potent metaphor, superlative + negative noun, intensifier + harm noun, or critical alert phrase.", "method": "llm_batch", "batch_id": "batch_2_15960", "batch_size": 200, "batch_pos": 132, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment mentions scale ('small human trial', 'first half of 2023') but lacks a moderate verb from the approved list. It also discusses a plan ('plans to launch').", "method": "llm_batch", "batch_id": "batch_3_15140", "batch_size": 200, "batch_pos": 107, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
